Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Intravitreal injection of bevacizumab for retinopathy of prematurity.

Kuniyoshi K, Sugioka K, Sakuramoto H, Kusaka S, Wada N, Shimomura Y.

Jpn J Ophthalmol. 2014 May;58(3):237-43. doi: 10.1007/s10384-014-0310-z. Epub 2014 Feb 26.

PMID:
24566819
2.

Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.

Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR.

Ophthalmology. 2015 May;122(5):1008-15. doi: 10.1016/j.ophtha.2014.12.017. Epub 2015 Feb 14.

3.

An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.

Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN.

Am J Ophthalmol. 2013 Jan;155(1):150-158.e1. doi: 10.1016/j.ajo.2012.06.010. Epub 2012 Sep 8.

PMID:
22967867
4.

Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA; BEAT-ROP Cooperative Group..

JAMA Ophthalmol. 2014 Nov;132(11):1327-33. doi: 10.1001/jamaophthalmol.2014.2772.

PMID:
25103848
5.

Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.

Kim J, Kim SJ, Chang YS, Park WS.

Retina. 2014 Jan;34(1):77-82. doi: 10.1097/IAE.0b013e318296e26d.

PMID:
23807184
6.

Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.

Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, Purcaro V, Giannantonio C, Papacci P, Romagnoli C.

Ophthalmology. 2014 Nov;121(11):2212-9. doi: 10.1016/j.ophtha.2014.05.015. Epub 2014 Jul 4.

PMID:
25001158
7.

Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.

Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG.

Br J Ophthalmol. 2014 Apr;98(4):507-12. doi: 10.1136/bjophthalmol-2013-304109. Epub 2014 Jan 8.

8.

Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.

Nazari H, Modarres M, Parvaresh MM, Ghasemi Falavarjani K.

Graefes Arch Clin Exp Ophthalmol. 2010 Dec;248(12):1713-8. doi: 10.1007/s00417-010-1430-x. Epub 2010 Jun 27.

PMID:
20582706
9.

Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK.

Ophthalmology. 2011 Jan;118(1):176-83. doi: 10.1016/j.ophtha.2010.04.018. Epub 2010 Jul 29.

PMID:
20673589
10.

Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.

Chung EJ, Kim JH, Ahn HS, Koh HJ.

Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1727-30. Epub 2007 Aug 10.

PMID:
17690897
11.

Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.

Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, Dastjani Farahani A, Ebrahimi Adib N, Torabi H.

Acta Ophthalmol. 2016 Sep;94(6):e417-20. doi: 10.1111/aos.13008. Epub 2016 Mar 24.

PMID:
27009449
12.

Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB.

Am J Ophthalmol. 2013 Jun;155(6):1119-1124.e1. doi: 10.1016/j.ajo.2013.01.014. Epub 2013 Mar 12.

PMID:
23490192
13.

Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.

Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC.

JAMA Ophthalmol. 2015 Apr;133(4):391-7. doi: 10.1001/jamaophthalmol.2014.5373.

PMID:
25569026
14.

Intravitreal low-dosage bevacizumab for retinopathy of prematurity.

Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC.

Acta Ophthalmol. 2014 Sep;92(6):577-81. doi: 10.1111/aos.12266. Epub 2013 Sep 11.

15.

Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?

Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmström G.

Acta Ophthalmol. 2013 Mar;91(2):170-5. doi: 10.1111/j.1755-3768.2011.02351.x. Epub 2012 Jan 23.

16.

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Honda S, Hirabayashi H, Tsukahara Y, Negi A.

Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3. doi: 10.1007/s00417-008-0786-7. Epub 2008 Mar 5.

PMID:
18320201
17.

[Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].

Autrata R, Senková K, Holousová M, Krejcírová I, Dolezel Z, Borek I.

Cesk Slov Oftalmol. 2012 Feb;68(1):29-36. Czech.

PMID:
22679695
18.

Intravitreal bevacizumab monotherapy for retinopathy of prematurity.

Şahin A, Şahin M, Cingü AK, Çınar Y, Türkcü FM, Yüksel H, Kaya S, Arı Ş, Caça İ.

Pediatr Int. 2013 Oct;55(5):599-603. doi: 10.1111/ped.12124. Epub 2013 Jul 30.

PMID:
23659781
19.

Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.

Isaac M, Tehrani N, Mireskandari K; Medscape..

Eye (Lond). 2016 Mar;30(3):333-41. doi: 10.1038/eye.2015.289. Epub 2016 Feb 12.

20.

Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7.

Chhablani J, Rani PK, Balakrishnan D, Jalali S.

Semin Ophthalmol. 2014 Jul;29(4):222-5. doi: 10.3109/08820538.2013.835842. Epub 2013 Oct 11.

PMID:
24117452

Supplemental Content

Support Center